List view / Grid view
5 September 2014 | By Abbott
Abbott announced that it has received CE Mark for its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for people with diabetes...
5 September 2014 | By GlaxoSmithKline
ViiV Healthcare announced that the European Commission has granted marketing authorisation for Triumeq® (dolutegravir 50mg / abacavir 600mg / lamivudine 300mg) tablets...
4 September 2014 | By Andrew Lloyd & Associates
Nosopharm announces its in vitro and in vivo findings for a novel antibacterial class, Odilorhabdins, which has the potential to combat antibiotic resistance...
4 September 2014 | By Roche
Roche announced that Arthur D. Levinson has resigned from the Board of Directors, effective immediately. Arthur D. Levinson made this decision so as to avoid any conflict of interest given his role as Chief Executive Officer at Calico...
4 September 2014 | By Masters
Masters Speciality Pharma signs agreement for the exclusive distribution of Ferriprox® (deferiprone)...
3 September 2014 | By GeNeuro
GeNeuro SA, a pioneer of new therapies for neurology disorders, announced positive results from a one-year, open-label extension of a Phase IIa study...
3 September 2014 | By The University of Nottingham
New research from The University of Nottingham looks set to improve screening for new cancer drugs and drug delivery systems specifically designed for children with brain tumours...
3 September 2014 | By kdm communications
Cresset is pleased to announce that Selvita S.A., a drug discovery company located in Krakow, Poland, has licensed Cresset’s Forge and Spark...
3 September 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced data from a subgroup analysis of the phase 3 ENGAGE AF-TIMI 48 study, that explores the relationship between edoxaban dose, concentration and anti-factor Xa activity in patients with non-valvular atrial fibrillation...
3 September 2014 | By Novo Nordisk
The Lancet Diabetes & Endocrinology has published the phase 3a DUAL™ I study investigating IDegLira (insulin degludec/liraglutide; Xultophy®) − once-daily, single injection insulin degludec (Tresiba®▼ ) and liraglutide (Victoza®)...
3 September 2014 | By Boehringer Ingelheim
New data presented indicate that kidney function decline is less pronounced in patients with an irregular heartbeat who are treated with Pradaxa® (dabigatran etexilate) compared to warfarin...
3 September 2014 | By European Medicines Agency
The European Medicines Agency is pleased to announce two new appointments to its management team...
3 September 2014 | By Teva
Court decision invalidating AZ's patent supports Teva’s launch of DuoResp Spiromax® in UK...
3 September 2014 | By Novartis
Novartis announced that new analyses to be presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, USA from September 10-13, 2014...
3 September 2014 | By Merck
Merck announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company’s investigational anti-PD-1 antibody...
